Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction

Disruption of Allergenic Activity of the Major Grass Pollen Allergen Phl p 2 by Reassembly as a Mosaic Protein

(2014) N. Mothes-Luksch et al.   JOURNAL OF IMMUNOLOGY

Vaccines for allergy

(2012) Birgit Linhart et al.   CURRENT OPINION IN IMMUNOLOGY

Long-term clinical and immunological effects of allergen immunotherapy

(2011) Aarif O. Eifan et al.   Current Opinion in Allergy and Clinical Immunology

Covalent Coupling of Vitamin D3 to the Major Cat Allergen Fel d 1 Improves the Effects of Allergen-Specific Immunotherapy in a Mouse Model for Cat Allergy

(2011) Jeanette Grundström et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS

(2011) Katarzyna Niespodziana et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy

(2011) Margitta Worm et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

In Vitro Evolution of Allergy Vaccine Candidates, with Maintained Structure, but Reduced B Cell and T Cell Activation Capacity

(2011) Ola B. Nilsson et al.   PLoS One

Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy

(2010) T. Saarne et al.   ALLERGY

From Allergen Genes to Allergy Vaccines

(2010) Rudolf Valenta et al.   Annual Review of Immunology

Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer

(2010) Raffaela Campana et al.   MOLECULAR IMMUNOLOGY

GA2LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe

(2009) G. J. Burbach et al.   ALLERGY

The Major Cat Allergen, Fel d 1, in Diagnosis and Therapy

(2009) Hans Grönlund et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy

(2009) Nicole Schmitz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy

(2008) J. M. Martínez-Gómez et al.   ALLERGY